RecruitingPhase 4NCT06972732

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

A Randomized, Open-label, Active-controlled, Parallel, Multicenter, Phase IV Clinical Trial to Compare the Efficacy and Safety of Switching Metformin+SGLT2-i+Dipeptidyl Peptidase-4-inhibitor(DPP-4-i) to Metformin+SGLT2-i+TZD in Patients With Type 2 Diabetes

Sponsor

Boryung Pharmaceutical Co., Ltd

Enrollment

204 participants

Start Date

Jun 11, 2025

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes

Summary

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing three different oral diabetes medication combinations — all including metformin — to see which works best at controlling blood sugar in people with type 2 diabetes. **You may be eligible if...** - You are 19 years or older - You have been diagnosed with type 2 diabetes - You are willing to participate voluntarily **You may NOT be eligible if...** - You have serious kidney or liver disease - You have type 1 diabetes - You have participated in another clinical trial recently (within the past 8 weeks) - Your doctor does not think you are suitable for the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.